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ABSTRACT 
Analysis of Binding Affinity in Drug Design Based on an Ab-initio Approach.  
(May 2009) 
Pablo Felix Salazar Zarzosa, B.S., University of Piura, Peru 
Chair of Advisory Committee: Dr. Jorge Seminario 
 
 Computational methods are a convenient resource to solve drawbacks of drug 
research such as high cost, time-consumption, and high risk of failure. In order to get an 
optimum search of new drugs we need to design a rational approach to analyze the 
molecular forces that govern the interactions between the drugs and their target 
molecules. The objective of this project is to get an understanding of the interactions 
between drugs and proteins at the molecular level. The interaction energy, when protein 
and drugs react, has two components: non-covalent and covalent. The former accounts 
for the ionic interactions, the later accounts for electron transfer between the reactants. 
We study each energy component using the most popular analysis tools in computational 
chemistry such as docking scoring, molecular dynamics fluctuations, electron density 
change, molecular electrostatic potential (MEP), density of states projections, and the 
transmission function. 
We propose the probability of transfer of electrons (transmission function) 
between reactants in protein-drug complexes as an alternative tool for molecular 
recognition and as a direct correlator to the binding affinity.  The quadratic correlation 
that exists between the electron transfer rate and the electronic coupling strength of the 
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reactants allow a clear distinguishability between ligands. Thus, in order to analyze the 
binding affinity between the reactants, a calculation of the electronic coupling between 
them is more suitable than an overall energetic analysis such as free reaction energy. 
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1. INTRODUCTION 
 
1.1 REALITY OF DRUG RESEARCH 
 
 
The discovery of new drugs is one of the most challenging and exciting tasks in 
science. For example, the average cost out-of-pocket per new drug (linking both the cost 
of unsuccessful drugs and the ones that obtained marketing approval) in 2000 was $401 
million. Capitalizing over the time expended in the project of about 12 years (average 
time to get a drug to the market), at a rate of 11%, the amount rises to $800 millions 1. 
Comparing the costs over the last 20 years, as shown in figure 1, there is an increase in 
the total cost at an annual rate of 7.4% above the general price inflation. There are 
several hypotheses for the increase in the clinical test cost: the focus on treatments for 
chronic and degenerative diseases that are generally more expensive; and the increase of 
investigated drugs turning in larger and longer recruits of patients at higher costs. Notice 
that, the slow increasing rate cost in the preclinical tests is mainly because of new 
computerized discovery technologies such as high throughput screening (HTS) and 
combinatorial chemistry.  
 
Figure 1: Estimated cost of drugs ( Ref 1) showing the slower increase rate of 
preclinical than clinical tests because of the use of computerized methods. 
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1.2  COMPUTER AIDED DRUG DESIGN 
 
 
Efforts, mainly from pharmaceutical companies, for reducing the costs and 
increasing efficiency of new drugs have made of computational and molecular modeling 
methods a key step in the drug discovery pipeline as shown in figure 2. 
 
Figure 2: Drug discovery pipeline vs Computer aided drug design2. Applications of 
computational methods in the drug design process. 
 
Computational chemistry and molecular modeling play an important role in the 
drug discovery process allowing a rational approach for the development of new 
potential drugs 3.  The first step in the drug discovery process is the target identification 
of an enzyme, protein or DNA sequence related to the dysfunction. The conventional 
approach for target identification consists of the comparison of functional genomics 
from normal and abnormal human’s tissues. Using computational bioinformatics tools, 
we identify the protein that is transcript in the abnormal gene code. Another approach is 
the reverse docking: an existing drug with known activity is docked it against a protein 
database; the protein hits go through a homologous analysis to find similar proteins. 
Finally, the relation of the heat proteins with the disease is validated using experimental 
procedures. 
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The next stage is the lead discovery and optimization.  Here the first step is the 
use of combinatorial chemistry and high-throughput screening (HTS) to screen many 
thousands of biologically active compounds in a short time. The improvement of library 
strategies, design principles, scaffold design, solid-phase methods and a new approach 
called dynamic combinatorial chemistry make of combinatorial chemistry a powerful 
tool for researchers. But, combinatorial chemistry also gives rise to a large number of 
compounds that are not suitable for synthesis as drug molecules. Therefore, the analysis 
of large dataset of drugs needs an efficient method for the discrimination of the ligands, 
resulting in lower number of potential leads. The method also has to be able to 
recognize, optimize and find new drug compounds by predicting, rationalizing and 
estimating their properties.  
In the next stage of the drug discovery process, we distinguish two cases when 
the three-dimensional structure of the target protein is not available and when is known.  
In the first class known as ligand-based drug design, one tries to relate electronic and 
structural properties with the known activities of the training test of drugs. As an 
example we have the comparative molecular field analysis (CoMFA) 4, in which the 
activity of known set of molecules is correlated with a steric and electrostatic field 
generated along the molecule.  In order to generate the field, we have to align the 
molecule in a 3-dimensional space following a suitable criteria such as maximizing the 
steric overlap following pharmacophore theories 5,6, or basing on automated field fit 
methods 7. Even though the results are promising, the strong dependence of CoMFA on 
the quality of the alignment rule makes the results unstable. In the line of ligand-based 
drug design, several quantum mechanics studies have been also reported 8,9.  
When the three-dimensional structure of the target protein is known, the analysis 
of the receptor-ligand interactions is directly done through parametric relations of 
electrostatic, van der Waals, hydrogen bond, aromatic and hydrophobic interactions.  
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Computational techniques to predict drug-likeness properties such as absorption, 
distribution, metabolism, excretion and toxicity (ADMET) have been developed as well. 
This technique, made of regression equations and/or neural networks trained on 
experimental data, reduces the costs of late stage preclinical and clinical trials. 
 
 
1.3  PROBLEM STATEMENT 
 
 
Computer aid drug design (CADD) is a combined procedure from theoretical and 
experimental aspects of established sciences as biochemistry, biophysics, chemistry, and 
computer science. In the first stages of CADD of the drug discovery process, 
combinatorial chemistry has made available large libraries of potential ligands for a high 
throughput screening (HTS), but yielding a large number of active compounds 
unsuitable for chemical synthesis10. To reduce the number of active compounds and 
increase the effectiveness of the drugs we need a rational protocol procedure based on 
first-principles that maximizes the chances of finding, discrimination and optimization of 
new drugs. In structure based drug design, inexpensive and fast docking algorithms 
based on scoring functions derived from force fields are used for a static search of the 
conformational orientation of the ligands inside of the active site of the receptor 
molecule. The search goes until an energetic minimum system is found. Having the total 
energy as a parameter, the set of ligands are ranked.  
The many degrees of freedom of protein-drugs systems make the search of a 
global minimum in the potential energy surface of the receptor-ligand complex a big 
task. And it turns out to be more complicated since the nuclei fluctuations of the 
reactants, due to thermal and vibrational energies, help to overcome several barriers of 
their complex potential energy surface.  Furthermore, thermal and vibrational energies 
strongly influence thermodynamic properties such as free energy, which is 
conventionally related to the binding affinity of the ligand-receptor. To overcome the 
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nuclei fluctuations problem, molecular dynamics and Monte Carlo methodologies 11,12, 
computationally more expensive than docking scoring, and free energy perturbation and 
thermodynamic integration techniques 13 are used in the determination of the free energy 
of the reactants. But the accuracy of the free energy calculations (based on force fields 
parameters) is insufficient to estimate slight energy differences of the ranked drugs. 
Therefore, the correlation of the free energy with the binding affinity lacks of reliability. 
Instead of calculating the free energy, one could also analyze the binding affinity based 
on qualitative properties such as fluctuation distances between the protein and the ligand, 
or root mean square deviations of the ligands over the trajectory. 
Any improvement on the Docking scoring or the MD approaches comes from ab-
initio calculations and experimental information. Thus, we need a model for the analysis 
of binding affinity based on ab-initio methods that help us to explain and quantify the 
structural and interaction features in a distinguishable and accurate manner. First 
principles methods solve not only all the nuclear motions: thermal, vibrational and 
orientational fluctuations; they also consider the electronic structure in an explicit 
manner. At least in the reactive site, we will have a chemical accuracy of the multiple 
interactions concerned, such as electrostatic forces, hydrogen bonding, Van der Waals 
interactions and bonded interactions.  
Among all quantum chemistry techniques, density functional theory (DFT) 
provides the best compromise between accuracy and cost. The applications of DFT in 
the study of protein-ligand interactions are wide 14-17. Common analysis at this level of 
theory is based on the study of molecular orbitals, binding energies, molecular 
electrostatic potentials, density of states projections and structural conformations of 
biomolecular complexes. But the quadratic relationship between the electronic coupling 
strength and the rate of electron transfer motivate us to emphasize the study of the 
electron transfer as a correlator to the binding affinity.  
The breakpoint of the study of electron transfer rates starts in the earlier 80’s 
with the Nobel Prize winner Rudolph A. Marcus and his document “Electron transfer in 
6 
 
 
chemistry and biology”. Since then, further study of electron transfer in biological 
context has been done 18 along with computational approaches 19. 
The nature of our variable is based on the electron transfer in biological 
processes. Even though the functions of electron transfer in protein-ligand complexes are 
not well understood yet, almost all the biological processes go along a series of transfer 
of electrons until a determined function is accomplished.  In some way, nature must 
discriminate between ligands according to the transfer rate of electrons in order to make 
it specific and efficient.  
The physical basis of the interaction energy relies on fundamental variational 
principles that govern the chemical reactivity. The interaction energy is decomposed in 
two complementary components: the electron transfer and the electrostatic contribution. 
The first is associated with the covalent bonding and is described by the variational 
principle with respect to the electron density: for the two compounds (receptor and 
ligand) interact, a rearrangement of the electron density, mainly in the interface, must 
occur until the energy of the complex is minimized. The electrostatic contribution is 
associated with uncovalent bonding and is explained by the variational principle with 
respect to the external potential: for two reactants come together, a rearrangement of the 
nuclei and charges must occur until the energy of the complex is minimized.  
We propose the following protocol: solving the nuclear motion problem without 
considering the electronic part using Docking and Molecular Dynamics methods. Then 
we solve the electronic wavefunction using ab-initio approaches and calculate the 
protein-drug electronic coupling.  
  
7 
 
 
1.4  APPROACH TO SOLVE THE PROBLEM 
 
 
Relying on variational principles implies a calculation based on first principles 
theories, but the simulation would result impractical for large protein-ligand systems in 
terms of computational costs.  
In order to facilitate the search of an energy minimum configuration, we use the 
Born-Oppenheimer approximation: as electrons move much faster than the nuclei, the 
electrons are considered moving in a potential created by fixed nuclei. Thus, we separate 
the configuration problem in two, one for the nuclei and the other for the electrons. We 
use force field based methods to approach the solution of the nuclei without considering 
the electrons explicitly. Then, we fix the new configuration of the atoms, and try to solve 
the electronic part by using a self-consistent calculation. 
The protocol proposed to solve the nuclei motion starts with a docking 
calculation. Knowing the 3D configuration of the target molecule and of the different 
drugs, we try to find, by scoring functions, a minimum orientational mode of the ligand 
in the active site of the receptor. We add explicitly solvent molecules (water) to the best 
ranked configuration from the DOCK results. After that, we start the molecular 
dynamics simulation. We make a minimization by steps: first we minimize the solvent 
molecules with the ligand and the receptor fixed; then we unfix all the hydrogen from 
the receptor and the ligand, keeping also free the solvent molecules; and finally we let 
free all atoms of the system. After the minimization, we heat the system quasi-
adiabatically until 298K and then, we equilibrate the system at constant pressure of 1 
atm. and 298K. By this procedure we try to not denaturalize the conformation previously 
obtained from the DOCK results and reach a conformation under living conditions. 
For the electronic part, we approximate the analysis to be local.  Therefore, for an 
ab-initio studio we restrict the calculation to a certain region of the active site, and we 
make a self-consistent field calculation using the density functional theory (DFT) 
approach. Instead of solving the wavefunction, as in standard ab-initio methods, DFT 
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yields the electron density energy of a polyatomic system from its atomic structure, 
based in the existence of a one to one relation between the electron density and its 
external potential. The Hamiltonian and overlap matrices are solved and used to 
calculate the electron transfer rate between the reactants. 
Finally, we create large libraries with the electron transfer behaviors between 
several combinations of common functional fragments of drugs and all the known amino 
acids, and use them as new tools for molecular recognition. The libraries with electron 
transfer behaviors can be used at every step of the drug design.  When the structure of 
the target molecule is not known (ligand-based drug design), we make use of the known 
activity of the drugs and correlate it with any structural or electronic property of them, 
this procedure is known as Quantitative Structure Activity Relationship (QSAR).  The 
created libraries will serve as a resource for new relationships. In Structure Based Drug 
Design (SBDD), when the protein is known in a 3D configuration, we could include the 
libraries to create new scoring functions for the search of conformational orientations of 
the drug inside of the active site.  And obviously in De Novo design (the optimization 
and creation of new drugs), the electron transfer characteristics would be a new variable 
to be included in the evolutionary algorithms general used in the growing fragment by 
fragment of the drug. 
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2. METHODS 
 
2.1  BINDING AFFINITY AND THE HSAB PRINCIPLE 
 
 
Binding affinity is a constant that estimates the tendency of two systems 
(generally one in much larger concentrations than the other) to dissociate, usually 
defined as the inverse of the dissociation constant:  
[C]
[P][L]
=dK  ... eq. 1 
 
where [P], [L], [C] mean concentrations of the protein, ligand and the complex 
respectively. Clearly, as the concentration of the complex (protein and ligand bonded) 
increases, the dissociation constant goes down and the binding affinity high.  
We should notice that a major property in drug research is the activity of the 
drug, defined as the concentration needed to activate or inactivate a specific target 
molecule. How do we estimate the binding affinity from computational chemistry?  
Many statements to predict the tendency of the reactions has been proposed over 
the last 30 years. After definition of electronegativity, by Parr 20, as the desire of a 
molecule to accept electrons, or strictly speaking, the energy needed/obtained to 
remove/add an amount of electron density at space r; the principle of electronegative 
equalization came up, in which the energy is minimized only if the electronegativity (the 
negative of the chemical potential) is equalized. Thus, the same tendency in many 
similar ways such as in acid-base reactions, donor-acceptors, oxidation-reduction were 
proposed 21,22. The electronegativity, χ, is then the variation of the energy with respect to 
the electron density, as in eq. 2, and it is also the negative of the chemical potential, µ. 
µ−=





δρ
ρδ
−≡χ
)(
)(
)(
r
E
r
 
... eq. 2 
One approximation of the electronic chemical potential, µ, is to relate it to the 
electron affinity, A, and ionization potential, I 
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2
)( AI +
−≈µ
 
... eq. 3 
   
As the first derivative of the energy with respect to the electron density is 
important, the second derivative should be as well, as proposed by Parr 20. Defined as 
chemical hardness, the second derivative of the energy with respect to the number of 
electrons can  be approximated as well in terms of electron affinity, A, and ionization 
potential, I: 
≈−≈





δ
δ
≡η AI
N
E
2
2
 ... eq. 4 
The Hard Soft Acid Base principle states that hard acids tend to associate with 
hard bases and soft bases tend to associate with soft acids. Its basis relies in the two 
components of the interaction energy and their relationships to the chemical potential 
and hardness.   
The first component is due to the electron transfer when the two reactants come 
together; they go through changes in the electron density between the reactants lowering 
the energy until the chemical potential is equalized,    
)(2
)( 2
BA
AB
etE η+η
µ−µ
−=∆  ... eq. 5 
here Bµ , Aµ , Aη  and Bη  denote the chemical potential and the hardness of the 
acid and the base involved in the reaction; and oµ  is the chemical potential after the 
reaction.  At similar strengths of chemical potential, the electron transfer is proportional 
to the softness (inverse of the hardness), explaining the tendency of soft molecules to 
react each other.  
The second component corresponds to the non-bonded interactions. Once the 
chemical potential is equalized the system goes through changes in the external potential 
at a constant chemical potential as expressed by:   
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)( BA
BA
qq rr
qq
E
+
=∆  ... eq. 6 
expressing the energy that stabilizes the system of two opposite charges when they 
approach to each other. For hard reagents, which generally are highly charged, electron 
transfer becomes unimportant the electrostatic interaction dominates in the system. 
Another change in the reaction is the polarization of the pseudo acids and bases, 
which lowers the energy by:  
4
2
4
2
)(2
)(
)(2
)(
BA
BA
BA
AB
pol rr
q
rr
q
E
+
α
−
+
α
−=∆   ... eq. 7 
αA and αB mean the polarizability of the reactants. But induced charges are only present 
when highly charged molecules react, that is, when electrostatic interactions are present 
as well. Quantitativily the former one is dominant, so generally the polarizability term in 
neglected. 
It is also possible quantify, in the same terminology, the non-bonded interactions 
of neutral or small charged components. Those kinds of interactions are called the 
London dispersion interaction: 
 6)(2
3
BA
BA
BA
BA
London rr
E
+
αα
ε+ε
εε
−=∆  ... eq. 8 
iε  represents the average excitation energy of the molecule. From the previous 
approximation ( )( HOMO-LUMO≈η ), the chemical hardness is approximately equal 
to the first excitation energy: 
6)(2
3
BA
BA
BA
BA
London rr
E
+
αα
η+η
ηη
−=∆  ... eq. 9 
It can be proved (not shown here) that the hardness is inversely proportional to 
the radius of the active site of interaction and to the polarizability coefficient, but in 
different degrees. From that follows that:  
7
4
6
2
)(
)(
2
3
BA
BA
r
London
c
c
E
η+η
ηη
−=∆ α  ... eq. 10 
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2.2 ELECTRON TRANSFER THEORY 
 
 
Classical theory of long distance electron transfer reactions between reactants, in 
which the interaction of the relevant electronic orbitals is weak, is described by the 
Fermi’s golden rule (equation 11). According to the Fermi’s rule the first order rate 
constant is proportional to the square of the coupling, HAB, of the wavefunctions of the 
reactants:  
FCHk AB *
2 2
h
π
=  ... eq. 11 
The second term FC is the “Franck-Condon” factor, which is a sum of products 
of overlap integrals of the vibrational and solvational wavefunctions of the reactants 
with those of the products suitably weighted by density of nuclear states.  is the 
reduced Planck constant equal to 6.58211899×10−16 eV·s.  
The separation of the two components (electrons and nuclei) is allowed by the 
Franck-Condon principle: since the electrons transferred are light particles, during the 
actual electron transfer the nuclei do not have time to change their positions, and then 
the transfer occurs only at near nuclear configurations for which the total potential 
energy of the reactants is equal to the products.  
A simplified example of a one-dimensional potential energy profile is given in 
figure 3. The electron transfer only occurs at the intersection of those two curves. In 
order for the reactants to reach it, thermal, vibrational and orientational coordinates are 
needed. The probability of going from the reactants (pink curve) to the products (blue 
curve) surface depends on a number of factors such as the extent of coupling of the 
electronic orbitals of the two reactants and their electronic motion.   
 Figure 3: Potential energy surface of reactants and products. Starting from the 
minimum of the reactants surface, thermal fluct
intersection where electron transfer 
 
uations take the system to the 
takes place and the complex is formed.
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2.3  DOCKING 
 
 
Molecular docking is the prediction and ranking of the conformational complex 
structure as a result of the chemical reaction of a given ligand and a receptor of known 
structure.  
There are two main issues in protein-ligand docking. The first is the functions 
that are going to score or rank every conformation. The second is the search algorithm 
between all positions and orientations, thus yielding huge number degrees of freedom. If 
the algorithm searches the best conformation going through all the degrees of freedom 
(with some conformation exceptions like the structure of a benzene ring for example), 
we call it a systematic algorithm. Sometimes it also uses a likelihood function, generated 
either by Monte Carlo methods or genetic algorithms in order to converge faster to a 
minimal conformation. 
Different approaches in the score functions have been developed such as force 
fields that parameterize the movement of the atomic centers by potential functions 23,24; 
empirical scoring functions that calibrate the receptor-ligand interactions based on 
complexes of known affinity 25-27; or statistical potentials based on the distribution of 
distances between atoms 28-30. 
Furthermore two characteristics of proteins are also important. One is the 
flexibility: x-ray structure shows that the ligands are buried or covered by the protein 
between 70 to 100 percent of their surface area. And the other is the solvation: it has 
been proved that the entropic effects of the water medium are crucial in the 
conformation and affinity of the complexes. The flexibility is solved by increasing the 
degrees of freedom of the atoms in the active site; on the other hand, the solvation is 
compensated implicitly in the score functions.   
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2.4  MOLECULAR DYNAMICS 
 
 
Molecular dynamics can serve as a search algorithm to explore the 
conformational space, and then use random snapshots of the complexes of the MD 
simulation as initial conformations for the docking scoring. Also, the rigid and flexible 
part of the receptor can be explored by MD and then, restrict the docking search 
algorithm to the most flexible section in order to reduce the degrees of freedom. 
After the docking process, MD can be used to relax the entire system; include the 
solvent molecules in an explicit manner; and compute, although it is highly expensive, 
the binding free energy. The computation of the free energy can be done either by free 
energy perturbation methods which are highly accurate but its constrained to similar 
ligands for a consensus comparison; or by linear integration energy methods where more 
empirical data are used, thus loosing accuracy. 
Since at this stage the objective is still a discrimination of the ligands, a 
qualitative analysis is still relevant. One type of analysis is looking at the atomic position 
fluctuations of the ligand inside of the active site, or the bond distance changes along the 
simulation. The basic correlation here is: the less flexible the more stable. The number 
and distribution of the H-bonding and ionic bonding between the reactants is also an 
indicator of the stability. The accessible surface area of the ligand in the active site is 
correlated with the flexibility as well.   
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2.5  AB-INITIO: ELECTRON DENSITY CHANGE 
 
 
One method to solve the Schrödinger equation: 
Ψ=Ψ++=Ψ EVVTH eeext )(
^^^^
 ... eq. 12 
where 
^
H  is the Hamiltonian operator for a system of nuclei and electrons. The 
Hamiltonian operator is composed of three contributions; 
^
T  is the operator for the 
electron kinetic energy contribution, ext is the operator for the potential energy of the 
electrons in the external field generated by the nuclei and, ee is the operator for the 
energy of all the electron-electron interactions. In Density Functional Theory (DFT), the 
wavefunction, Ψ , is dependent of the three spatial coordinates and the spin of every 
electron, thus the wavefunction is a function of 4N variables (N is the number of 
electrons).  The Schrödinger equation is solved using DFT, which is based on the 
Hohenberg-Kohn-Sham theorems 31,32; using the electron density ρ as a variable, which 
dependent on only three variables (three coordinates in 3D space).  
The total energy is 
xcext Vrdrd
rr
rre
drrrVTE +
−
ρρ
+ρ+ρ=ρ ∫∫
→→
→→
→→
→→
'
|'|
)()(
2
)()()()(
'2
 ... eq. 13 
where the electron-electron interactions have been decomposed in two components (the 
last two terms of equation 13). The first of those (the integral term) accounts for the by 
the columbic repulsion energy of the electrons. This integrand (also called Hartree term) 
depends only on the local electron density through the entire space and it represents the 
potential energy induced by the repulsion of the electrons at distance | '
→→
− rr | over the 
entire space. The second term is the so called exchange and correlation energy that 
accounts for the rest of the electron-electron interactions; the exchange is a non-local 
contribution that arises from the antisymmetric nature of the wavefunction. The 
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correlation term, instead, accounts for the effect of Coulomb correlation upon many-
electron wavefunction. It is important to notice that the exchange and correlation term 
includes also the contribution of the kinetic energy arising from the electron-electron 
interactions; in other words, the kinetic energy difference from the total system and a 
non-interacting system.  
The electron density for a closed shell system is written as a sum of squared one-
electron wave-functions,  
∑
→
ψ=ρ
N
i
i rr
2|)(|2)(  ... eq. 14 
The one-electron wave-function solutions are expanded as a linear combination 
of atomic-like orbitals kφ :  
∑
→→
φ=ψ
k
kiki rcr )()(  ... eq. 15 
where the ikc  are eigenvectors coefficients corresponding to the linear expansion of the 
one-electron wave function, iψ , in atomic orbitals.  
The first Hohenberg-Kohn theorem states that external potential extV  is uniquely 
determined by the electron density. Then, since the Hartree term and the exchange and 
correlation terms depend on the electron density, ρ, and in turn the electron density 
corresponds to a unique N-electron Hamiltonian; the solution is obtained iteratively. The 
solution of the Kohn-Sham equation starts with a guess of the electron density, which is 
built using semiempirical approaches, and then the Kohn-Shan matrix and a first 
eigenfunction solution are calculated. The new eigenfunction yields a new electron 
density and so on. The process is repeated until the total energy is minimized within 
certain threshold.  
The electron density allows us to estimate any property of the nuclei-electrons 
system. Qualitatively, we can estimate the strength of the bond using the electron 
density. In any electron transfer reaction, even in outer-sphere or weak coupled, a 
change of the electron density from the most negative electrostatic molecule to the most 
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positive occurs forming a covalent bond, even though the bond is still weak. Then the 
total amount of charge density transferred is proportional to the strength of the bond.  
 
 
2.6  AB-INITIO: MOLECULAR ELECTROSTATIC POTENTIAL (MEP) 
 
 
The electrostatic potential )r(V
→
 due to the nuclei and electrons of a molecule at 
a point r in the space is defined by  
∑ ∫ →→
→→
→
→
−
ρ
−
−
=
A
A
A
|r'r|
'rd)'r(
|rR|
Z
)r(V  ... eq. 16 
where ZA is the charge on nucleus A, located at RA, and )'(
→
ρ r is the electron density at 
any point '
→
r . The first component is a positive contribution from the nuclei, ZA and the 
second is a negative contribution from all the electrons (integral covers the whole space), 
thus the net potential is positive, zero or negative, depending on which contribution is 
the more dominant33. Negative regions are more likely to be attacked by an electrophile 
(positively charged) species.   The preference depends, on the value of the negative 
potential. Some negative regions are due to the π-orbitals of unsaturated molecules such 
as those from benzene rings, heteroatoms fragment of an amino acid with carbonyl lone 
pairs.  
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2.7  AB-INITIO: DENSITY OF STATES PROJECTIONS 
 
 
The density of states (DOS) spectra represents the occupancy distribution of 
electrons along the energy states. According to the tight binding theory, a narrow band 
of the DOS is an indicator of the small coupling between the valance states (the states of 
the reagents responsible for the reaction), meaning a more reactive system34. The 
explanation is that electrons can exist only at quantized energy levels, and the 
accumulation of electrons at a specific energy is only possible at a non-interactive 
system. For example, the DOS of the surface atoms of a cluster shows a narrow and 
sharp peak instead of the broad band DOS of the bulk atoms of the same cluster. A high 
coordination number of the atoms in the bulk cluster broads the distribution of the 
energy levels. It follows that a change from a narrow to a broad peak after the reaction 
indicates a strong chemisorption between the reactants (protein and drug).   
Also, a downshift in energy of the valance states after the interaction means a 
strong chemisorption, since the electrons are trying to go to more stable states.  
 
 
2.8  AB-INITIO: TRANSMISSION FUNCTION 
 
 
Starting from the Marcus theory, a model of the current-voltage behavior adapted 
for a donor-bridge-acceptor system is described by the Landauer formula 35 (the full 
mathematical derivation can be found elsewhere 36). The current of electrons with energy 
between E and E + dE is determined by, 
∫
∞
∞−
−= dEVEfVEfVET
h
e
VI )],(),()[,(
2
)( 2211  ... eq. 17 
where T(E,V) is the transmission coefficient (probability per transport channel), fi(E) is 
the Fermi-Dirac distribution and Vi is the bias voltage.  
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In molecular junctions, the transmission function T is calculated using the 
Green’s function approach: 
)()( +ΓΓ= MM GGTraceET  ... eq. 18 
Γ  represents the coupling protein-drug: 
][ ++ ττ−ττ=Γ ggi  ... eq. 19 
where ττ+g  is a Hermitian conjugate self-energy matrix to describe the coupling 
between the reactants. MG describes the retarded Green function of the drug molecule 
affected by the protein.  
From quantum chemical calculations we can approximate these functions into 
matrix forms. We use a partitioned Hamiltonian in atomic basis to describe the retarded 
Green function: 
1
1
1
0
0
)(G
−
−
++
−










τ−
τ−−τ−
τ−
=
g
HE
g
E c = 










2221
21
1211
GGG
GGG
GGG
M
MMM
M
 ... eq. 20 
g represents the protein, as it was a substrate, and again τ describe the protein-drug 
coupling. Hc is the Hamiltonian of the isolated drug and E is the electron energy. 
 
Solving the inverse we find that GM is equal to: 
1]2[ −+ ττ−−= gHEG cM  ... eq. 21 
We assign the components of the inverse of GM to the submatrices of the 
partitioned KS Hamiltonian, which in turn depends of a linear combination of atomic 
like orbitals: 










=
PPDP
DPDDDP
PPDP
KS
HHH
HHH
HHH
H  ... eq. 22 
where the subscripts P and D refer to the protein and the drug, respectively. 
Then HDD is assigned to Hc, HPD to τ and HDP to τ*. Furthermore, it has to be 
noticed that the real KS Hamiltonian matrix solved is of the form: 
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Ψ=Ψ eSH KS  ... eq. 23 
instead of: 
Ψ=Ψ EH  ... eq. 24 
where S is the overlap matrix and e are the eigenvalues, then the corresponding 
transformation has to be done in order to these matrices to be Hermitians. 
Full detailed of the methodology to calculate the transmission function, but in a 
sense of molecular conduction in nano-junctions, can be found in ref. 37-39 and it has 
been implemented in the GENIP program 40-43. 
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3. TEST CASES 
 
3.1 OXIDATION AND REDUCTION AFFINITIES ON CATALYTIC SURFACES 
 
 
As preliminary results, we test the use of the electron transfer as a correlator for 
binding affinity. We build junctions based on known electro-catalytic interactions such 
as hydrogen oxidation and oxygen reduction in platinum surfaces. The results of this 
work were also published in our previous paper44. The systems, as shown in figure 4, are 
made of a bulk of glycine amino acids (green surface) that will resemble the biological 
environment. The bulks end up in platinum or palladium terminals. Between the 
terminals we have the test ligands, oxygen and hydrogen dimmer. Even though these 
systems are not so similar to real cases, both share a common characteristic: the electron 
transfer in the active site. To calculate the electron transfer characteristics, showing it in 
an I-V behavior, the procedure differs slightly from the proposed in section 1.4.  
The GENIP program estimates the current-voltage behavior using the bulk of 
glycine as source of electrons. The terminals are either the platinum or palladium atoms. 
The flux of electrons goes from terminal to terminal through the bridge molecules that 
are either the oxygen or hydrogen dimmer. As stated before, a higher current correlates 
with a stronger reactivity between the compounds. 
      
Figure 4: Picture of the test junction Pseudo protein (green) - Platinum (blue) – O2 
(red) - Platinum-Pseudo protein. Similar tests were constructed by replacing the O2 
with H2 and platinum with palladium  
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A 
 
B 
Figure 5: I-V curves for A: G-Pt-HH-Pt-G with H2 dissociated (blue) and H2 
bonded (pink) showing higher current for H2 bonded, B: G-Pt-OO-Pt-G with O2 
dissociated (green) and O2 bounded (red) showing higher current for O2 
dissociated, C: G-Pd-OO-Pd-G (green) and G-Pt-OO-Pt-G (maroon) showing 
higher current for palladium. 
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C 
Figure 5 Continued 
 
The results in figure 5 are correlated with experimental tendencies.  The current-
voltage curve for the platinum-hydrogen interactions (figure 5A) shows a higher a 
current when the hydrogen dimmer is bonded rather than when it is dissociated. On the 
other hand, the platinum-oxygen curve (figure 5B) shows the opposite trend: a higher 
current when the oxygen is dissociated than when is bonded. The behavior corresponds 
with experimental formation of hydroxides on the platinum surfaces, due to the high 
affinity for oxygen dissociated.  
Differential experimental heats of oxygen absorption on platinum surfaces 
(figure 6) show a down peak at oxygen saturation: thermal desorption spectra has shown 
that the energy of adsorption of oxygen dissociated on platinum surface is about 340 
kJ/mol, and about 40 kJ/mol for oxygen molecular. According to figure 6, the oxygen is 
presented in a dissociative manner on the platinum surface at the beginning of the 
adsorption. Only when the metal surface is saturated of oxygen, the molecular oxygen is 
adsorbed.  
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Figure 6: Differential heats of oxygen adsorption on 0.5 and 1 wt% Pt/TiO2 
measured at 30 degrees Celsius45. This shows that the adsorption of oxygen in the 
platinum surface is in a dissociative manner until the surface is saturated 
 
Another comparison between different catalytic surfaces is done by replacing the 
platinum atoms with palladium (figure 5C). The I-V results show what is known: a 
higher affinity or reactivity for platinum surfaces than for palladium.  
 
 3.2 PIM-1 KINASE: IMPORTANCE, KNOWN 
We test our protocol 
important mediators of cytokine signaling pathways in hematopoietic cells, and they 
contribute to the progression of certain leukemias and solid tumors. 
well-known drugs active to the PIM
(http://www.bindingdb.org
bisindolylmaleimides (BIM)
identified as very potent inhibitors of PIM
charges in the specificity of the protein
test set of drugs by protonating each 
shown that going from the zwitterion to the protonated state of a histidine
located in the active site can totally change the 
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Figure 7: Structures of known drugs for the PIM
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We also do a characterization of the active site that 
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active site shows a negative charge in the bottom due the presence of Aspartic acid (Asp) 
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with positive amino acids on the top, such as Lysine (Lys) and Arganine (Arg); and also 
with hydrophobic interactions between the rings of the drugs and the hydrophobic amino 
acids. We approximate the reaction between the protein and the drugs to be local, so for 
a further ab-initio analysis, we restrict the system to consider the atoms within a radius 
of 5.0 A from the drugs.   
 
Figure 8: Imaging 47of the characterization of the active site of PIM-I kinase 
showing a dominant number of negative amino acids on one side of the active site 
and positive and hydrophobic on the other. 
28 
 
 
4. RESULTS 
 
4.1 DOCKING CALCULATION 
 
 
Receptor preparation: PIM-1 kinase crystal structures were obtained from the 
Protein Data Bank (http://www.rcsb.org).  Further modification of the structure was not 
needed.  Hydrogen atoms were then added to the entire receptor. Gasteiger charges were 
computed by ANTECHAMBER 48 and added using the USCF Chimera program47. 
Ligand preparation: Ligands were prepared from crystal structures reported in 
BindingDB webpage (http://www.bindingdb.org).  Bond and atom types were checked, 
and hydrogens were added. Gasteiger charges were calculated for all ligands.  
Molecular docking: Docking of the three complexes (figure 9A) was performed 
using DOCK 6.0.0 49 and its accessory programs.  DMS (dot molecular surface) tool 50 
was used to create a molecular surface of the receptor.  The Sphgen program49 was then 
used to create a set of spheres orthogonal to the molecular surface of the protein. The 
resulting file was edited to include only spheres within a cutoff distance of 10.0 Å from 
the ligand (figure 9B).  This distance was sufficient to include the entire active site.  
Scoring and bump grids were then generated using GRID 51. Contact and energy scores 
were calculated using the AMBER99 parameter force field with an energy cutoff 
distance of 9A and a van der Waals repulsive exponent of 12. All other parameters were 
left as their defaults.  
The conformational search goes through the spheres center method. The center of 
the spheres represents the possible positions of the center of the atoms of the ligand. 
Depending of the search algorithm the ligand goes through several combinations of 
positions until finds a conformation with the lowest energy.  
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  A      B 
Figure 9: Imaging 47 of A) PIM-I Kinase (magenta), an oncogene-encoded 
serine/threonine kinase primarily expressed in hematopoietic and germ cell lines 
showing the active site with its ligand (blue). B) Schematic picture of the modeling 
of the active site by the sphere centers method. 
 
 
 
Table 1: Enthalpy of formation of known drugs obtained from the DOCK program, 
and experimental values. Also a test of the results has been done for the Protonated 
states of the drugs showing indeed higher contributions of the electrostatic 
interaction, and similar values for the VDW contribution. 
Contribution (kJ/mol) 
Staurosporine BIM-8 BIM-11 
Neutral Protonated Neutral Protonated Neutral Protonated 
VDW contribution  -52.6 -40.4 -29.5 -28.9 -34.5 -37.6 
Elect. contribution  -3.5 -9.8 -5.1 -21.4 -0.5 -11.1 
TOTAL  -54.1 -50.2 -34.6 -50.2 -35.0 -48.7 
Exp. enthalpy of 
formation  -33.8 
 
-41.3 
 
-13.7 
 
Exp. free energy  -48.0  -43.0  -35.5  
 
The results of Table 1 show that at least the trend of the experimental free energy 
is barely followed by the docking calculations. 
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4.2 MOLECULAR DYNAMICS SIMULATION 
 
 
After the docking scoring calculation, we take the best scored conformation of 
the receptor-ligand complex (the one with the lowest energy). We use the Perl script to 
generate the force field parameter file of the unknown atoms of the drugs based on the 
GAFF force field. At the same time, the Perl script adds water atoms into the system. 
Then we start minimizing the water molecules and keeping all the others atoms of the 
receptor-ligand fixed. At this step, the minimization is of 1000 steps and we consider the 
Van der Waals and electrostatic interactions of the atoms separated by three bonds with 
a cutoff of 8 A. A second consequent minimization is done keeping unfixed all the 
hydrogens atoms of the system along with the water molecules for 10000 steps as well, 
and considering the VDW and columbic interactions the atoms separated by two bonds. 
Finally, we minimize the system for 25000 steps let them free all the atoms. Then, we 
heat the system very slowly with an increment of 0.001 K for every time step (1 fs.) until 
298K. After that we equilibrate the system for 50 ps with 1 fs time step, at 1 atm. and 
298K with a rescale of the temperature every 10 fs. 
We do a qualitative analysis of the fluctuations of the drugs in the active site 
(figure 10 and 11), basing in the statement: “the less flexible, the stronger the binding”. 
We calculate the RMSD fluctuation of the heat atoms (C, O and N) of the drugs along a 
short range of time after the equilibration stage. The fluctuations shown in figure 10 
determine that staurosporine is the most stable drug. In specific, the order of stability is 
staurosporine > BIM-11 > BIM-8. Instead, the protonated set of drugs shows a slight 
different trend (figure 11): staurosporine > BIM-8 > BIM-11 
 Figure 10: RMSD fluctuations of the heat atoms of the neutral set of drugs in the 
active site along the equilibration
 
A. Staurosporine (Mean: 0.21) 
 
B. BIM-8 (Mean: 0.30) 
 
C. BIM-11(Mean: 0.28) 
 step. Their fluctuations are correlated with the 
free energy of the reaction. 
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Figure 11: RMSD fluctuations of the heat atoms of the protonated set of drugs in 
the active site showing the sensitivity of the syste
 
 
A. Staurosporine (Mean: 0.22) 
 
B. BIM-8 (Mean: 0.34) 
 
C. BIM-11(Mean: 0.37) 
m to a change of charges.
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4.3 AB-INITIO: ELECTRONIC BINDING ENERGY AND THE HSAB 
PRINCIPLE RESULTS 
 
 
After the molecular dynamics simulation, we take the “average conformation” of 
the system and restrict it to consider only the atoms in the active site (a radius of 5 A 
with respect to the drug). “The average conformation” is made up of the average 
cartesian coordinates of the atoms during a short range of time after the equilibration 
stage. The conformation at the equilibration stage accounts for the changes in the 
position of the nuclei due to the thermal energy. Reducing the system to consider only 
the active site allows to use more expensive method/basis set in the ab-initio approach. 
In order to account for the non-bonded interactions that are usually overestimated by 
conventional DFT methods like B3PW91, we use a novel DFT-like functional M05-2X 
that uses a different proportion of the Hartree-Fock exchange potential. All the ab-initio 
calculations in this project has been done using Gaussian 0352. 
  
Table 2: Electronic binding energy and driving force energy.   
Energy (eV) 
Staurosporine BIM-8 BIM-11 
Neutral Protonated Neutral Protonated Neutral Protonated 
Reorganization 
energy  3.35 
9.94 
0.91 
6.35 
1.72 
9.88 
Driving force  0.57 4.18 0.04 1.18 1.37 4.39 
 
We define as the electronic binding energy to the energy difference associated to 
the redistribution of the electrons in the reaction of the drug and protein. The 
redistribution of the electrons is determined by the self-consistent calculation of the 
Schrödinger equation (eq. 12). The electron density, ρ, experience iterative changes until 
the total energy of the system (eq. 13) reaches a minimum. 
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 In order to calculate the electronic binding energy, we calculate the energy of the 
complex with an ab-initio approach and compare it to the energy of the reactants alone, 
but maintaining the geometry as they are in the complex. Table 2 shows the electronic 
binding energy for all cases. At the redistribution of the electrons during the reaction, we 
have to recognize the two interaction energy components. One associated to the 
equalization of the chemical potential forming bonds, and the other involved in the 
electrostatic interaction due to the polarization of the charges.  
The driving force energy is a renamed variable of the electron transfer 
contribution described before (Section 2.1). Having two components at different 
chemical potentials, a movement of the electron density from the high to low potential 
must occur in order to equalize the chemical potential. The transfer of charges represents 
a decrease of the electrostatic interaction. In my opinion, it is impossible from eq. 5 to 
predict the energy related to the change of electron density since it does not consider the 
properties of the final product. Instead, if the trend determined by the energy change of 
eq. 5 is followed, this energy change estimates the ionic character of the interaction 
before the reaction instead, that is, a sort of potential to the reaction due to the columbic 
charges.  
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4.4  AB-INITIO: ELECTRON DENSITY CHANGE 
 
 
As stated before (section 2.4), a higher charge transfer from the most negative to 
the most positive electrostatic molecule translates in a stronger bond. The calculated 
total charge transfer using the Mulliken population analysis is shown in Table 3. 
  
Table 3: Total charge transfer from the protein to the drugs (neutral/protonated). 
Staurosporine BIM-8 BIM-11 
-0.5/-0.9 -1.1/-0.4 -0.1/-0.3 
 
In order to observe the local changes at every point of the active site, we have 
projected the electron density change in a 3-D feature. As shown in figure 13, the 
electron density change in the drug has two distinguishable regions, one will accumulate 
electrons (blue surfaces) coming from negative amino acids (and other regions of the 
drug), and the other will show depletion of electrons (red surfaces) that goes either to 
other regions of the drugs or to electrostatic positive regions of the protein. The overall 
of blue surfaces minus red surfaces will mean the total electron density transfer. 
A. Stau
Figure 12: Electron density ch
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4.5  AB-INITIO: MOLECULAR ELECTROSTATIC POTENTIAL (MEP) 
 
 
Analogously we present the 3-D feature of the molecular electrostatic potential of 
the final complexes (Figure 13). The MEP helps us to identify spots where the 
electrostatic interaction is strong in the entire space of the active site. Notice that in 
BIM-11, we had to go to higher isodensity surfaces to ensure a MEP with similar 
characteristics as in Staurosporine and BIM-8. The reason is that Staurosporine and 
BIM-8 has, from the electron density change results, a stronger electrostatic interaction 
than BIM-11(or weaker covalent bonding). Then, their electrons are more condensed in 
their nuclei. Thus going to higher isodensity surfaces means calculate the MEP at closer 
distances from the radius, compensating its higher condensation of electrons. 
 
    
A. Staurosporine-
Figure 13: Molecular electrostatic potential
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B. BIM-8 -Protein complex 
 
    
C. BIM-11 - Protein complex 
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4.6  AB-INITIO: DENSITY OF STATES (DOS) PROJECTIONS 
 
 
There are two characteristics to look up in the DOS projections that dictate the 
reactivity of the protein and their drugs. In short, the change from narrow to broad bands 
close to the Fermi level is a consequence of the strong chemisorption of the drug in the 
protein due to the stronger coupling between the valance states. Furthermore, a shift of 
the bands to more stable energy levels (shift to the left) is proportional to the strength of 
the chemisorption.  
The DOS projections for each set of drugs, neutral and protonated, are shown in 
figure 14 and 15, respectively (shaded curves are the projection of the protein before the 
reaction and light curves are after the reaction). The combination of the two features of 
the DOS ranks the reactivity of every drug, following a similar trend determined by the 
electronic binding energy. staurosporine and BIM-8 does not show a change in their 
sharpness. Instead, they show downshifts in the energy of the bands. A greater shift in 
the case of staurosporine, compared to BIM-8, accounts for its greater electronic binding 
energy. Instead, BIM-11 shows a change into more wide bands but the increase in 
reactivity is diminished by an upshift of the energy of the bands. In the protonated set, 
all the reactions have almost the same downshift to more stable energy levels. But 
Staurosporine and BIM-11 have changes to more broad bands, accounting for higher 
electronic binding energies.  
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A. Protein affected by Staurosporine (neutral) 
 
B. Protein affected by BIM-8 (neutral) 
 
C. Protein affected by BIM-11 (neutral) 
Figure 14: Density of States projections of the protein PIM-1 Kinase before 
(shaded curves) and after the reaction (light curves) with the neutral drugs. 
Change to broad curves and downshifts in energy mean the strength of the 
chemisorptions 
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A. Protein affected by Staurosporine (protonated) 
 
B. Protein affected by BIM-8 (protonated) 
 
C. Protein affected by BIM-11 (protonated) 
Figure 15: Density of States projections of the protein PIM-1 Kinase before 
(shaded curves) and after the reaction (light curves) with the protonated 
drugs. Change to broad curves and downshifts in energy mean the strength 
of the chemisorptions 
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4.7  AB-INITIO: TRANSMISSION FUNCTION 
 
 
The transmission functions dictate the probability of electron transport between 
donor and acceptors and, at the same time, is an estimation of the electronic coupling 
between the reactants. Actually the transmission is proportional to the square of the 
electronic coupling, making of the transmission function a variable sensitive to any 
change in the interactions of the reagents. There are several approaches to calculate the 
electronic coupling, but so far, no one has applied the Landauer approach to biological 
systems like we did. And the reason may be because the Landauer approach is based on 
molecular junctions. But looking at their derivation, the Landauer approach started with 
the same Marcus definition of the transfer rate of electrons. Figure 16 shows the results 
for both sets (a different scaling factor for each set has been applied in the calculation of 
the transmission, then comparison between the two graphs is not reliable), the high peak 
in the transmission of Staurosporine is a consequence of its strong covalent interaction; 
and also similar peaks of BIM-11 and Staurosporine in the protonated cases account for 
their similar strength of coupling.    
  
 
Figure 16: Transmission functions for the neutral set (left) and for the protonated 
set of drugs (right). Higher peaks mean higher rate transfer of electrons. 
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5.  CONCLUSIONS 
 
 
 We have tested the most relevant computational chemistry techniques towards a 
fully understanding of the molecular interactions in biological systems like protein-
ligand interactions.  
In order to find a best correlation of the binding affinity with some electronic, 
thermodynamic or conformational property; we have analyzed the components of the 
interaction energy involved in the reaction, mainly, through an ab-initio approach. 
We have proposed a protocol to analyze protein-drug systems by starting from 
docking calculation and molecular dynamics in order to take into account the nuclei 
fluctuations at natural conditions. Then we did a local study using first principles to 
account for the interactions of electrons, keeping fixed the nuclei (based on the Frank-
Condon principle and/or the Born-Oppenheimer approximation). 
We use the PIM-1 Kinase, responsible for diseases such as leukemia, and their 
known active drugs in order to test the analysis tools. The small difference in free energy 
makes of the discrimination of the drugs hard to do. Further molecular dynamics 
simulations are needed, but at this point where no electrons are treated explicitly, only 
qualitative analysis like RMSD fluctuations is done. The results show a better agreement 
with their respective experimental free energy 
Then, we restrict the ab-initio studio to the active site of the protein since it is 
believed that any chemical reaction would have to be local. We calculated their 
electronic binding energies and we used the electron density change and molecular 
electrostatic potential to analyze the covalent and ionic interactions, respectively. A 
higher electron density change between the PIM-1 Kinase and their drugs corresponded 
to a stronger covalent bond. On the other hand, localized spots of electrostatic potential 
(positive and negative) are representation of strong ionic interactions. 
We analyzed the chemisorption of the drugs by looking up the density of states 
projections of the protein before and after the interaction. We extrapolated the 
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conclusions from the tight binding theory, based on metal surfaces, and apply them to 
biological systems. The results are in agreement with the electronic binding energies. 
For example, the protonated set of drugs showed a higher effect in the downshift of the 
energy levels of the protein (shift towards more stable energies). Even more, 
Staurosporine and BIM-11 of the protonated set showed a change to broad bands due to 
a stronger chemisorption, accounting for higher electronic binding energies with respect 
to BIM-8. 
Finally, we proposed a methodology based on the Landauer approach to calculate 
the electronic coupling which in turn will represent the transfer rate of electrons. The 
results showed that Staurosporine (neutral) accounts for the highest rate validating their 
lowest experimental free energy.  
The combined analysis of the computational chemistry techniques used in this 
project gives us a better insight of the different molecular interactions in protein-ligand 
complexes, and furthermore it let us be able to distinguish their different interaction 
components.  
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